Mannitol 50g/500ml (10%) infusion Viaflo bags Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

mannitol 50g/500ml (10%) infusion viaflo bags

10%) infusion viaflo bags (baxter healthcare ltd - mannitol - infusion - 100mg/1ml

BAXTER POTASSIUM CHLORIDE 40 mmol and 0.9% SODIUM CHLORIDE 1000 mL intravenous infusion bag Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

baxter potassium chloride 40 mmol and 0.9% sodium chloride 1000 ml intravenous infusion bag

baxter healthcare pty ltd - potassium chloride, quantity: 2.98 g/l; sodium chloride, quantity: 9 g/l - injection, intravenous infusion - excipient ingredients: water for injections; hydrochloric acid - the baxter potassium chloride and sodium chloride intravenous infusion is indicated as a source of water and to restore electrolyte balance as required by the patient's clinical condition, such as hypokalaemia.

Mannitol 15 % w/v Viaflo inf. sol. i.v. Bèlgica - anglès - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

mannitol 15 % w/v viaflo inf. sol. i.v.

baxter sa-nv - mannitol 15 g/100 ml - solution for infusion - mannitol 150 mg/ml - mannitol

NIMODIPINE JUNO nimodipine 10 mg/50 mL concentrated intravenous infusion solution vial Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

nimodipine juno nimodipine 10 mg/50 ml concentrated intravenous infusion solution vial

juno pharmaceuticals pty ltd - nimodipine, quantity: 10 mg - injection, intravenous infusion - excipient ingredients: citric acid; sodium citrate dihydrate; water for injections; ethanol; macrogol 400 - prophylaxis and treatment of ischaemic neurological deficits caused by cerebral vasospasm after subarachnoid haemorrhage following ruptured intracranial aneurysm, in patients who are in good neurological condition post-ictus, e.g., hunt and hess grades i-iii (see section 5.1 pharmacodynamic properties).

Mannitol 20% Malta - anglès - Malta Medicines Authority

mannitol 20%

demo s.a. pharmaceutical industry 21st km national road athens - lamia 14568 krioneri, greece - mannitol - solution for infusion - mannitol 200 mg/l - blood substitutes and perfusion solutions

Polyfusor mannitol 10% infusion 500ml bottles Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

polyfusor mannitol 10% infusion 500ml bottles

fresenius kabi ltd - mannitol - infusion - 100mg/1ml

MANNITOL Irlanda - anglès - HPRA (Health Products Regulatory Authority)

mannitol

baxter healthcare limited - mannitol - solution for infusion - 15 %w/v - mannitol

MANNITOL Irlanda - anglès - HPRA (Health Products Regulatory Authority)

mannitol

baxter healthcare limited - mannitol - solution for infusion - 10 per cent - mannitol

MANNITOL injection, solution Estats Units - anglès - NLM (National Library of Medicine)

mannitol injection, solution

icu medical inc. - mannitol (unii: 3owl53l36a) (mannitol - unii:3owl53l36a) - mannitol injection is indicated for the reduction of: - intracranial pressure and treatment of cerebral edema; - elevated intraocular pressure. mannitol injection is contraindicated in patients with: - known hypersensitivity to mannitol [see warnings and precautions (5.1)] - anuria [see warnings and precautions (5.2)] - severe hypovolemia [see warnings and precautions (5.4)] - pre-existing pulmonary vascular congestion or pulmonary edema [see warnings and precautions (5.5)] - active intracranial bleeding except during craniotomy. risk summary the available case report data with mannitol over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. mannitol crosses the placenta and may cause fluid shifts that could potentially result in adverse effects in the fetus (see data) . no adverse developmental effects from mannitol were reported in published animal studies; however, fluid shifts occurred in fetal ewes in response to mat

MANNITOL injection, solution Estats Units - anglès - NLM (National Library of Medicine)

mannitol injection, solution

henry schein, inc. - mannitol (unii: 3owl53l36a) (mannitol - unii:3owl53l36a) - mannitol injection is indicated for the reduction of: - intracranial pressure and treatment of cerebral edema. - elevated intraocular pressure. mannitol injection is contraindicated in patients with: - known hypersensitivity to mannitol [see warnings and precautions (5.1)]. - anuria [see warnings and precautions (5.2)]. - severe hypovolemia [see warnings and precautions (5.4)]. - pre-existing severe pulmonary vascular congestion or pulmonary edema [see warnings and precautions (5.5)]. - active intracranial bleeding except during craniotomy. 8.1 pregnancy risk summary the available case report data with mannitol over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. mannitol crosses the placenta and may cause fluid shifts that could potentially result in adverse effects in the fetus (see data).no adverse developmental effects from mannitol were reported in published animal studies; however, fluid shifts occurred in fetal ewes i